Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Citi lifts price target on St James's Place, reiterates 'buy'

(Sharecast News) - Citi lifted its price target on St James's Place on Monday to 1,280p from 1,010p and reiterated its 'buy' rating as it updated its model ahead of full-year results on 27 February. "Our FUM estimates increase by 5%, driven by market appreciation and stronger-than-expected Q4 flows," it said.

Citi said this drives a circa 10% increase to its outer-year cash earnings per share estimates.

The bank said its H2 2024 underlying cash EPS of 41.1p is 2% above consensus.

"However, our cash EPS is 8-9% above consensus for FY 2026/27, driven by FUM estimates that are 3-4% above consensus," it said. "We model 3.3% net flows for FY 2025. In addition to our estimate changes, our discounted cash flow now fully includes gestation run-off, while we also increase our assumed outer-year profit after tax margin on mature FUM from 25 basis points to 28bp."

This compares to its estimated 27bp margin in 2027 and 31bp in 2028.

"This drives our target price from £10.10 to £12.80, implying 18% total return from the current share price," Citi said.

At 1525 GMT, the shares were up 2.5% at 1,130p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.